Melina Claussnitzer

Assistant Professor

Harvard University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Single-cell transcriptomic and proteomic technologies enable molecular profiling of immune cells at scale but provide limited access to cellular phenotypes shaped by spatial organisation, organelle architecture and cytoskeletal remodelling. Here we present TGlow, a scalable high-content imaging platform optimized for systematic single-cell phenotyping of primary human lymphocytes. TGlow integrates cyclic immunofluorescence, deep z-stack confocal imaging, and open-source data processing pipelines, including both classical and self-supervised vision transformer-based feature extraction, to jointly quantify cellular morphology, organelle organization, and immune activation states. Applied across over 400,000 primary human T cells spanning CD4 + activation time courses, drug perturbations, CRISPR knockouts and CD8 + T-cell exhaustion, TGlow resolves distinct and reproducible phenotypic states. We uncover dose-dependent and mechanism-specific drug phenotypes, such as defective endoplasmic reticulum polarisation under mycophenolic acid and tofacitinib. We show that mitochondrial clustering reveals activation– and cell-cycle–linked remodelling programs, CRISPR perturbations map gene-specific phenotypes that reposition cells along activation trajectories, and we identify a previously unrecognised collapse of cytoskeletal architecture in exhausted CD8 + T cells. TGlow provides a scalable framework for high-dimensional phenotyping of lymphocyte states advancing functional genomics, perturbation screening and population-level immune profiling by resolving the morphological and functional heterogeneity of lymphocytes and enabling systematic linkage of genetic and pharmacological perturbations to cellular function.

Year:

2026

Alzheimer’s disease (AD) is marked by hallmark neuropathological changes in the brain. However, its upstream genetic determinants, beyond the central nervous system (CNS), remain largely unexplored. To that extent, we integrated human genomic data with cross-tissue and single-cell analyses across up to 40 peripheral tissues and 100 brain regions. We observed limited genetic enrichment in the CNS, with brain-resident microglia emerging as the sole enriched cell type. Instead, AD risk loci were predominantly enriched in peripheral immune compartments and immune-enriched barrier tissues, such as the lung and the digestive tract, and particularly within myeloid-lineage cells. Leveraging gene expression profiles from peripheral immune cells, we recreated an age-related susceptibility curve for AD, identifying ages 55-60 as a critical window for immune activation linked to AD risk. Our findings position the peripheral immune system as a central contributor of disease susceptibility, opening new directions for early intervention beyond the brain.

Year:

2026

Variants in the familial hypercholesterolemia gene LDLR —the most important genetic driver of cardiovascular disease—can raise circulating low-density lipoprotein (LDL) cholesterol concentrations and increase the risk of premature atherosclerosis. Definitive classifications are lacking for nearly half of clinically encountered LDLR missense variants, limiting interventions that reduce disease burden. We tested the impact of ~17,000 (nearly all possible) LDLR coding variants on both LDLR cell-surface abundance and LDL uptake, yielding sequence–function maps that recapitulate known biochemistry, offer functional insights, and provide evidence for interpreting clinical variants. Functional scores correlated with hyperlipidemia phenotypes in prospective human cohorts and augmented polygenic scores to improve risk inference, highlighting the potential of this resource to accelerate familial hypercholesterolemia diagnosis and improve patient outcomes.

Year:

2025

The 9p21.3 locus is the strongest genetic association with coronary artery disease (CAD), yet its causal mechanisms remain unresolved. We map the regulatory architecture of 9p21.3 in disease-relevant vascular cells, identifying 12 enhancers within the CAD risk haplotype that respond dynamically to inflammatory and metabolic stress in fibroblasts and smooth muscle cells. These activated states are enriched for CAD heritability, implicating stress-responsive vascular wall cells in disease pathophysiology. Dense CRISPRi tiling integrated with fine-mapping and genomic constraint across >500,000 individuals nominates MTAP as the effector gene, with rs1537371 as a likely causal variant. Perturbation and multi-modal analyses show that MTAP loss induces pro-fibrotic and angiogenic programs and sensitizes vascular cells to TGF- β –driven pathological transitions. Our findings reveal a vascular-specific enhancer network through which noncoding variation at 9p21.3 modulates CAD risk via MTAP —a previously unrecognized regulator of vascular remodeling located 269 kb from the risk haplotype. Highlights 9p21.3 CAD risk locus harbors 12 functional enhancers active in vascular wall cell types CAD heritability is enriched in stressed vascular fibroblasts and smooth muscle cells High-resolution CRISPRi-MAC-seq maps 9p21.3 enhancer-gene and SNP-gene interactions MTAP identified as a causal effector gene regulated by 9p21.3 fine-mapped and constrained variants MTAP modulates TGF-β-driven pathological vascular cell transitions

Year:

2025

Peroxisome proliferator-activated receptor γ (PPARγ) is the master regulator of adipogenesis, but the mechanisms underlying its strong induction in response to adipogenic cues are poorly understood. Using human mesenchymal stem cells as a model system, we show that the PPARG locus is primed for activation in the progenitor state by a highly connected enhancer community, which gets further activated and interconnected during adipogenesis. By systematically deleting individual enhancers in the community and interrogating the effect on enhancer function, connectivity and gene expression, we reveal important, non-redundant and cooperative roles of many enhancers. We show that the promoter-proximal enhancers and the downstream super-enhancer constituents cooperate in cis at early time points of differentiation, whereas at later timepoints PPARγ feedback-activates its own expression. Top-scoring non-coding cardiometabolic variants predicted to affect PPARG2 expression map to key enhancers in the community, indicating that regulation via these enhancers is important for human physiology.

Year:

2025

Adaptive thermogenesis in brown adipose tissue is regulated by PPARGC1A (PGC-1α), which could be affected by common polymorphism (rs8192678, Gly482Ser) that associates with metabolic disorders. We used CRISPR-Cas9 in immortalized human brown adipocyte cell line to edit the rs8192678 locus to evaluate the allele-dependent effects on cold response of brown adipocytes. In both 482Ser- and 482Gly-edited brown adipocytes, UCP1 expression increased after 6-hour cold exposure, but the increase was less pronounced in 482Gly cells, which also had lower mitochondrial activity. Furthermore, 482Gly PGC-1α had an almost two-fold longer half-life at 37°C, and four-fold longer half-life at 32°C, compared with the 482Ser variant. Despite the longer half-life, the 482Gly PGC-1α had lower activity, and was more prone to be retained in the cytoplasm after cold exposure. Our experimental data support gene x environment interactions between Gly482Ser and cold exposure in human brown adipocytes. These data support a novel molecular basis for the epidemiological observations that link the Gly482Ser polymorphism with obesity and related metabolic disorders.

Year:

2024

Overall adiposity and body fat distribution are heritable traits associated with altered risk of cardiometabolic disease and mortality. Performing rare variant (minor allele frequency<1%) association testing using exome-sequencing data from 402,375 participants in the UK Biobank (UKB) for nine overall and tissue-specific fat distribution traits, we identified 19 genes where putatively damaging rare variation associated with at least one trait (Bonferroni-adjusted P <1.58×10 -7 ) and 50 additional genes at FDR≤1% ( P ≤4.37×10 -5 ). These 69 genes exhibited significantly higher (one-sided t -test P =3.58×10 -18 ) common variant prioritisation scores than genes not significantly enriched for rare putatively damaging variation, with evidence of monotonic allelic series (dose-response relationships) among ultra-rare variants (minor allele count≤10) in 22 genes. Combining rare and common variation evidence, allelic series and longitudinal analysis, we selected 14 genes for CRISPR knockdown in human white adipose tissue cell lines. In three previously uncharacterised target genes, knockdown increased (two-sided t -test P <0.05) lipid accumulation, a cellular phenotype relevant for fat mass traits, compared to Cas9-empty negative controls: COL5A3 (fold change [FC]=1.72, P =0.0028), EXOC7 (FC=1.35, P =0.0096), and TRIP10 (FC=1.39, P =0.0157); furthermore, knockdown of PPARG (FC=0.25, P =5.52×10 -7 ) and SLTM (FC=0.51, P =1.91×10 -4 ) resulted in reduced lipid accumulation. Integrating across population-based genetic and in vitro functional evidence, we highlight therapeutic avenues for altering obesity and body fat distribution by modulating lipid accumulation.

Year:

2024

Collaborators (26)

Cecilia Lindgren

Steering Group Member

University of Oxford

UNITED KINGDOM
View details

Simon Georg Pfisterer

University of Helsinki

FINLAND
View details

Frederik Heymann Lassen

Research Scholar

Broad Institute

UNITED STATES
View details

Craig Glastonbury

Research Group Leader

Human Technopole

ITALY
View details

Susanne Mandrup

Professor at University of Southern Denmark

University of Southern Denmark

DENMARK
View details

Robert Hegele

Jacob J. Wolfe Distinguished Medical Research Chair in Human Gene Function

Western University

CANADA
View details

Paul Franks

Professor

Lund University Medical Faculty Foundation

SWEDEN
View details

Kenneth Matreyek

Assistant Professor

Case Western Reserve University

UNITED STATES
View details

Ruth Loos

The Charles Bronfman Professor in Personalized Medicine

Københavns Universitet

DENMARK
View details

Mafalda Bourbon

Invited Professor

Faculty of Medicine, University of Lisbon

PORTUGAL
View details

Charles B. Epstein

Broad Institute

UNITED STATES
View details

Jesper Grud Skat Madsen

Assistant Professor of Computational Biology

University of Southern Denmark

DENMARK
View details

Megan Lancaster

Assistant Professor

Ohio State University

UNITED STATES
View details

Andrew Glazer

Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Anke Husmann

Assistant Research Professor

University of Cambridge

UNITED KINGDOM
View details

Peter Spégel

Ass Prof

Lund University

SWEDEN
View details

Andrea Johanna Manrique Rincón

Staff Scientist

Wellcome Sanger Institute

UNITED KINGDOM
View details

Alexander Rauch

Associate Professor

University of Southern Denmark

DENMARK
View details

Daniel Esteban Coral Candelo

Lund University

SWEDEN
View details

María José Romero Lado

University of Copenhagen

DENMARK
View details

Frederick Roth

Professor and Chair

University of Pittsburgh

UNITED STATES
View details

Elena Navarro-Guerrero

Head of Functional Genomics

University of Oxford

UNITED KINGDOM
View details

Gosia Trynka

Science Director and Immune Genomics Group Leader

Wellcome Sanger Institute

UNITED KINGDOM
View details

Douglas Fowler

Professor

University of Washington

UNITED STATES
View details

Calum MacRae

Professor

Harvard University

UNITED STATES
View details

Tuomas Kilpeläinen

Assistant professor

Københavns Universitet

DENMARK
View details